Switzerland-based Ava has raised $2.6 million seed round for its wearable device that provides pregnant women with precise insights about the menstrual cycle. The money was provided by ZKB and Swisscom, two of the most renowned Swiss early stage investors, as well as a few business angels, including Yonca Even Guggenbühl (co-founder of MediService) and Dr. Valentin Chapero (former CEO of Sonova).

Also as part of the deal, Ava will strengthen its board of directors with Dr. Ruedi Gygax, former Managing Director of Novartis Venture Fund; and Renate Schreiber, former CEO of Medela.

“The money will be used to accelerate industrialization of the technology and to bring the product to market,” says Pascal Koenig, co-founder and CEO of Ava. “The trust from investors is a great motivation for our team to realize our vision and make a difference in women’s health.”

Ava has built up a database of six billion data points referenced to hormonal measurements.Ava’s sensor bracelet is designed to be worn at night, offering key cycle health information that precisely predict fertile days and ovulation in advance. The device thus helps couples maximize their chances to conceive and gives them certainty along their journey.

Supported by the University Hospital of Zurich, Ava has built up a database of six billion data points referenced to hormonal measurements. The technology will also be used detect pathologies during pregnancy, and for non-hormonal contraception.

Ava is currently building up an office in San Francisco to prepare market entry which is planned mid-2016.